Attached files

file filename
EX-7.1 - EX-7.1 - U.S. Stem Cell, Inc.d28625ex7-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


 

FORM 8-K

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 30, 2010


BIOHEART, INC.

 

(Exact name of registrant as specified in its charter)

Florida

 

(State or other jurisdiction of incorporation)

 

 

 

1-33718

 

65-0945967

  

 

 

(Commission File Number)

 

(IRS Employer Identification No.)

13794 NW 4th Street, Suite 212
Sunrise, Florida 33325

 

(Address of principal executive offices, including zip code)


(954) 835-1500

 

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


 

 

 

o

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

o

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


 

 

 

o

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

o

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 7.01

Regulation FD Disclosure.


On August 30, 2011, Bioheart, Inc. (the “Company”) mailed a Letter dated August 26, 2011 to its shareholders of record. A copy of the letter is filed herewith.




Item 9.01  Exhibits.


Exhibit Number

Description 


7.1

    Letter to Shareholders, dated August 26, 2011, filed herewith.










Signatures



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: September 6, 2011

 

 

 

 

 

 

BIOHEART, INC.
 

 

 

By:  

/s/ Mike Tomas  

 

 

 

Mike Tomas 

 

 

 

President & Chief Executive Officer 

 



Exhibits



7.1

    Letter to Shareholders, dated August 26, 2011, filed herewith.